{
    "clinical_study": {
        "@rank": "107451", 
        "arm_group": [
            {
                "arm_group_label": "Degarelix", 
                "arm_group_type": "Experimental", 
                "description": "50 women will be treated with degarelix 80mg in one administration"
            }, 
            {
                "arm_group_label": "Goserelin", 
                "arm_group_type": "Active Comparator", 
                "description": "goserelin 3.6mg monthly for three months"
            }
        ], 
        "brief_summary": {
            "textblock": "The long acting GnRH antagonist degarelix will be tested for the treatment of women with\n      endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom\n      disappearance and disease free time during follow-up will be the outcomes for establishing\n      which medical treatment is the best in endometriosis recurrence treatment."
        }, 
        "brief_title": "Degarelix in the Treatment of Endometriosis Recurrence", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Endometriosis", 
        "condition_browse": {
            "mesh_term": [
                "Endometriosis", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing\n      recurrence after surgery at least in 20-50% after 5 years of follow-up. The long acting GnRH\n      antagonist degarelix, which do not have the flare-up effect at the opposite of GnRH agonist\n      and strongly suppress LH secretion and thecal cell activity may show a better effects on\n      endometrial implants than GnRH agonist."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women affected by endometriosis showing recurrence of pain symptoms\n\n          -  previous surgery for endometriosis\n\n        Exclusion Criteria:\n\n          -  presence of other systemic diseases"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01712763", 
            "org_study_id": "C06/2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Degarelix", 
                "description": "50 women will be treated with degarlix 80 mg, in only one administration covering three months", 
                "intervention_name": "degarelix", 
                "intervention_type": "Drug", 
                "other_name": "firmagon"
            }, 
            {
                "arm_group_label": "Goserelin", 
                "description": "50 women will be treated with decapeptyl 3.6 every month for three months", 
                "intervention_name": "goserelin", 
                "intervention_type": "Drug", 
                "other_name": "decapeptyl"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Goserelin", 
                "Triptorelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Endometriosis", 
            "long acting GnRH antagonist", 
            "Degarelix", 
            "Recurrence", 
            "Pelvic Pain"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "contact": {
                "email": "marcandrea@hotmail.com", 
                "last_name": "MARCO SBRACIA, MD", 
                "phone": "+39065810461"
            }, 
            "contact_backup": {
                "email": "quelidebercia@hotmail.com", 
                "last_name": "FABIO SCARPELLINI, MD", 
                "phone": "+39068848013"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "zip": "00153"
                }, 
                "name": "Cerm-Hungaria"
            }, 
            "investigator": {
                "last_name": "MARCO SBRACIA, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment With Long Acting GnRH Antagonist Degarelix in Women With Endometriosis Recurrence", 
        "other_outcome": {
            "description": "endometriosis lesions regression during treatment evidenced by MRI scan", 
            "measure": "reduction of endometriosis lesions", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "overall_contact": {
            "email": "marcandrea@hotmail.com", 
            "last_name": "MARCO SBRACIA, MD", 
            "phone": "+39065810461"
        }, 
        "overall_contact_backup": {
            "email": "quelidebercia@hotmail.com", 
            "last_name": "FABIO SCARPELLINI, MD", 
            "phone": "+39068848013"
        }, 
        "overall_official": {
            "affiliation": "Centre for Endocrinology and Reproductive Medicine, Italy", 
            "last_name": "MARCO SBRACIA, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "time without pain symptoms due to the disease recurrence", 
            "measure": "disease free time", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01712763"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "time needed during treatment to improve the pain symptoms", 
            "measure": "time of disappearance pain", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "source": "Centre for Endocrinology and Reproductive Medicine, Italy", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre for Endocrinology and Reproductive Medicine, Italy", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}